首页> 中文期刊> 《国际妇产科学杂志》 >伏隔核因子1在卵巢癌化疗耐药中的研究进展

伏隔核因子1在卵巢癌化疗耐药中的研究进展

         

摘要

化疗耐药是制约卵巢癌治疗效果的主要原因之一,寻找逆转卵巢癌耐药的有效方法是当前国内外研究的热点。近年来研究表明,伏隔核因子1(nucleus accumbens-1,NAC-1)在卵巢癌中的过度表达不仅在其发生发展、转移复发中起重要作用,而且与化疗耐药密切相关。NAC-1通过调节药物耐药相关的多种信号通路,导致卵巢癌细胞对抗肿瘤药物的敏感性降低。因此以NAC-1为靶点逆转卵巢癌耐药可能为治疗开辟新的思路,NAC-1特异性抑制剂联合其他化疗药物有望成为卵巢癌新的治疗策略。现就NAC-1在卵巢癌化疗耐药中的研究进展进行综述。%Resistance to antineoplastic drugs is a major cause that leads to poor treatment effect in ovarian cancer. Finding effective ways of ovarian cancer chemoresistance reversal has become a hotspot at home and abroad. A rapidly growing number of recent studies shows that, overexpression of nucleus accumbens 1 (NAC-1) in ovarian cancer is not only involved in pathogenesis, progression, metastasis and recurrence, but also closely related with tumor resistance. NAC-1 regulates multiple signal pathways of ovarian cancer chemoresistance to reduce anti-tumor drugs sensitivity. Therefore, the specific targeting of NAC-1 could open new avenues for reversing ovarian cancer chemoresistance, the specific inhibition of NAC-1 activity in ovarian cancer cells combined with chemotherapy is expected to be an effective cancer treatment strategy. This article reviews the mechanism of NAC-1 in ovarian cancer chemoresistance.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号